Outpatient Mental Health and Substance Abuse Centers (U.S.)

NAICS 2022 code 621420 — an investor's primer

1. Overview

This is the network of clinics and centers that treat mental illness and addiction without an overnight stay: community mental-health and counseling centers, group therapy and psychiatry clinics, methadone and buprenorphine ("opioid treatment") programs, and the fast-growing tele-therapy platforms. NAICS — the North American Industry Classification System, the federal scheme used to sort businesses — assigns this activity code 621420. Federal data count roughly 16,800 establishments, ~321,000 workers, and ~$30.6 billion in annual receipts [1][2]. It sits inside a much larger behavioral-health economy, but as a distinct slice it is a professional-services business: revenue is visits times reimbursement, and the scarce input is licensed clinicians — not hard assets or consumer brands.

Why it matters to an investor: demand is large, under-served, and structurally growing (about 61.5 million U.S. adults had a mental illness in 2024 and only around half received treatment) [6], while payment is shifting toward parity with physical health [9]. It is also one of the most fragmented corners of health care — the four largest firms hold under 4% of revenue [2] — which has made it a magnet for roll-up strategies and, more recently, for regulatory scrutiny of those roll-ups.

• Public-market ways in are few and imperfect: a handful of listed operators, led by outpatient pure-play LifeStance Health and behavioral giant Acadia Healthcare, plus diversified hospital operator Universal Health Services and virtual-therapy platform Talkspace (being taken private by UHS). There is no dedicated exchange-traded fund.
• Private ways in dominate: private-equity-backed clinic and addiction chains, nonprofit and county providers, and venture-funded digital marketplaces (Headway, Grow Therapy, Rula, Talkiatry) own far more of the field than the public names do.

Our view: the long-term demand outlook is favorable, but returns depend heavily on reimbursement, clinician retention, billing discipline, regulatory compliance, and acquisition execution. Forward-looking judgments in this primer are flagged as such; everything else is reported fact with a citation.

---

2. What it is, and how it's structured

In scope (NAICS 621420): establishments with medical/clinical staff providing outpatient diagnosis and treatment of mental-health disorders and alcohol/drug abuse — patients who do not need a hospital bed [3]. In practice that means four business types:

1. Community mental-health & counseling centers — therapy, psychiatric evaluation, medication management, case management; often nonprofit or government-affiliated.
2. Outpatient substance-use / opioid treatment programs (OTPs) — the methadone and medication-assisted-treatment (MAT) clinics, plus outpatient detox and alcoholism programs.
3. Multi-site outpatient psychiatry/therapy groups — the for-profit roll-ups (e.g., LifeStance), often blending in-person and virtual visits, intensive outpatient (IOP) and partial-hospitalization (PHP) programs.
4. Virtual behavioral-health platforms — tele-therapy and tele-psychiatry billed to insurance.

Explicitly excluded — this is where federal counts undercount the broader "mental-health economy":

• Solo psychiatrists → NAICS 621112 (Offices of Physicians, Mental Health Specialists) [3].
• Solo/group psychologists, social workers, licensed counselors → NAICS 621330 (Offices of Mental Health Practitioners, except Physicians) [3]. Much U.S. outpatient therapy is delivered by these independent practitioners, who fall outside 621420.
• Inpatient psychiatric & substance-abuse hospitals → NAICS 622210 [3].
• Residential (non-hospital) rehab and group homes → NAICS 623220 [3].

Because the exact code turns on an establishment's primary activity and ownership, the boundary is fuzzy in practice.

Ownership mix: historically dominated by nonprofit and government community providers, with a rising for-profit layer — independent practices, hospital systems, physician groups, private-equity-backed platforms, and payer-affiliated networks all participate. The federal statistics do not give a reliable public-versus-private ownership split. Where the picture is clearest is addiction treatment: of the nation's roughly 1,900 opioid treatment programs, about 60% are for-profit, and roughly half of those are private-equity-owned — about 30% of all OTPs, versus an estimated ~7% private-equity ownership across behavioral-health facilities generally [22].

---

3. How big it is

Ground-truth U.S. federal statistics for NAICS 621420:

The Herfindahl-Hirschman Index is a standard concentration gauge; a reading of 9.2 against a 10,000 maximum is among the lowest in health care. Derived from the figures above: about 1.7 establishments per firm and roughly 19 employees per establishment. Mixing vintages (2022 receipts against 2023 establishment counts), that implies on the order of $1.8 million of revenue per establishment, and payroll runs near 57% of receipts — i.e., a labor-intensive, mom-and-pop-heavy industry in which nearly every operator clears the U.S. Small Business Administration (SBA) "small business" bar of $19 million in receipts. A private research estimate (IBISWorld) puts the same industry at roughly $31 billion in 2025, close to the Census figure [32].

Read these as two snapshots, not one income statement. Receipts are from 2022; employment and payroll from 2023. The ground-truth file supplies no patient volume, industry profit, payer mix, utilization, or nonemployer/government-provider totals — so those should not be inferred.

Undercount caveats (important):

• CBP excludes the self-employed and most government employees; the Economic Census generally excludes government-owned establishments and nonemployer (no-payroll) businesses [4]. Government-operated county and state clinics — a large share of actual public mental-health delivery — are largely captured under government accounts, not here. The true public footprint of outpatient behavioral care is bigger than $30.6 billion suggests.
• Because solo psychiatrists (621112) and independent therapists (621330) sit in adjacent codes [3], 621420 captures only the "center/clinic" slice of outpatient behavioral health. Broader "behavioral-health / addiction-treatment market" estimates that run to $140 billion-plus fold in those adjacent codes plus inpatient and residential care, and are not comparable to 621420.
• Low national concentration does not mean low local concentration: a clinic may face only a few meaningful rivals in a given county or insurance network.

---

4. The investable universe

Pure public plays are few; the industry is mostly private. Public figures below are as reported in recent filings and change with the market.

Publicly traded

None is a pure representation of the whole 621420 universe: LFST is the cleanest operating proxy for the insurance-billed outpatient model; ACHC and UHS add inpatient/hospital exposure; TALK represents virtual care but is primarily a merger play until the deal closes. LifeStance itself was taken private by TPG in 2020, then IPO'd in 2021, with sponsors TPG, Summit Partners and Silversmith once holding ~66% [19].

Major private operators and owners

Private ownership is not continuously disclosed; this list is illustrative, not a market-share ranking.

• BayMark Health Services (Webster Equity–backed) — the largest U.S. opioid-treatment operator, 400+ facilities across 35 states [20].
• New Season / Colonial Management and Pinnacle Treatment Centers — large private OTP/substance-use chains.
• Mindpath Health — outpatient psychiatry, therapy and telehealth; reported owners after a 2021 deal were Centerbridge Partners and Leonard Green & Partners [24].
• Newport Healthcare — a youth/family continuum (residential, PHP, IOP); Onex Partners took a majority stake in 2021 [25].
• Discovery Behavioral Health — 130+ programs spanning residential, PHP, IOP and online treatment; announced a restructuring and new (unnamed) majority owner in June 2026 [26].
• BrightView Health — a private outpatient addiction operator (medication, therapy, telehealth) [27].
• Connections Health Solutions — crisis-receiving and stabilization centers, adjacent to outpatient behavioral health [28].
• Digital, insurance-based platforms: Headway (~$2.3 bn valuation, 2024), Grow Therapy (unicorn, 2024), Rula (~$470 M annualized revenue), Talkiatry (~800 psychiatrists) — marketplaces that credential independent clinicians into insurance networks [21].
• Payer-owned provider arms: Optum Behavioral Care (UnitedHealth) and Evernorth Behavioral Care Group (Cigna); Optum also owns clinic assets such as Refresh Mental Health.
• Nonprofit & county providers / CCBHCs — the largest group by sheer count and the backbone of publicly funded care.

Takeaway: to own the outpatient mental-health theme in public markets, LFST is the pure-play while ACHC/UHS give diversified exposure; to own the addiction-treatment or digital-marketplace theme, you are largely in private markets.

---

5. How the money works

Owners make money on a simple identity: revenue = completed visits (or treatment episodes) × net reimbursement per service, earned across a payer mix — commercial insurers, Medicaid, Medicare, self-pay, employer contracts, grants and government contracts — against a cost base dominated by clinician pay. The levers:

• Payer mix is destiny. Medicaid is the single largest payer of behavioral health [8]. Acadia's book, for example, runs ~57% Medicaid, 26% commercial, 14% Medicare, 3% self-pay [16]. Commercial insurance pays the most per visit, Medicaid the least; the blend sets the ceiling on margin.
• Clinician productivity and utilization. Output is capped by how many clinicians you employ and how many billable visits each delivers. Recruiting and retaining licensed staff — in a country where roughly 157 million people live in a mental-health workforce-shortage area [7] — is the binding constraint. Wage inflation compresses margins directly.
• Center / clinic contribution margin. For a clinic operator, margin after clinician comp and facility cost is the key unit-economics number: LifeStance's "center margin" ran ~32% of revenue in 2024–25 [15]. Corporate overhead and de-novo (new-clinic) ramp then determine whether that drops to profit — LifeStance closed 82 underperforming centers in 2023 before turning profitable [15].
• OTP economics differ. Methadone/MAT clinics run a daily-dosing, high-frequency model: recurring per-patient revenue (often a bundled weekly Medicaid rate covering medication plus counseling), high census, sticky retention. That recurring cash flow is exactly what attracted private equity [22].
• Marketplace/platform economics. Headway, Grow and Rula take a cut of reimbursements (or charge providers a fee) for handling credentialing, billing and patient flow — an asset-light layer monetizing the independent clinicians who sit outside 621420 [21].

Watch-list metrics: visits per clinician and booked-slot utilization; new-patient wait time, cancellations and no-shows; same-center visit and revenue growth; net reimbursement per visit and payer mix; claims-denial rate and days in accounts receivable; clinician recruitment, turnover and vacancy; patient census and episode retention (OTPs); de-novo ramp; EBITDA (earnings before interest, taxes, depreciation and amortization) margin; and cash conversion after capex and acquisitions. "Capacity" here means licensed clinician hours and approved program slots — not factory utilization.

---

6. What drives demand

• Prevalence and the treatment gap. The Substance Abuse and Mental Health Services Administration (SAMHSA) reported that in 2024 about 61.5 million adults (23.4%) had any mental illness, while 32.0 million received mental-health treatment; among people needing substance-use treatment, 10.2 million received it [6]. That untreated majority is the industry's structural growth runway.
• The overdose/opioid epidemic sustains demand for MAT and OTP services.
• Workforce shortage sets the cap. As of July 1, 2026 the Health Resources and Services Administration (HRSA) listed 7,109 mental-health Health Professional Shortage Areas (HPSAs), covering 157.1 million people and requiring 7,825 additional practitioners to lift the designations [7]. Growth is often gated by hiring, not by need.
• Coverage and parity. Insurance expansion plus enforcement of mental-health parity (Section 7) push more care into billable, insured settings [9].
• Telehealth normalization. Post-2020 virtual care widened access and lowered the friction of a first appointment; Medicare revises its telehealth list annually and federal opioid-treatment rules have expanded telehealth options [13].
• Crisis-care build-out. SAMHSA's crisis framework links the 988 hotline, mobile teams and stabilization facilities to outpatient programs; better crisis systems funnel more referrals into outpatient and intensive-outpatient care.
• Destigmatization, especially among younger adults, is lifting help-seeking.

Net: demand is large, non-cyclical (behavioral-health need does not fall in recessions), and supply-constrained — an attractive combination, tempered by heavy reliance on government payers.

---

7. Regulation

This is a heavily regulated, licensure-gated industry. The main layers: state facility, clinician and telehealth licensing; Medicaid, Medicare and commercial payer enrollment/credentialing; federal parity and privacy rules; OTP certification; and fraud-and-abuse law (the False Claims Act and Anti-Kickback Statute). Key specifics:

• Mental Health Parity and Addiction Equity Act (MHPAEA, 2008). Bars insurers and group health plans from imposing worse limits on mental-health/substance-use benefits than on medical/surgical care; Medicaid managed care faces parity rules too [9]. A 2024 final rule tightened "non-quantitative treatment limitations" (prior authorization, network adequacy, reimbursement). In 2025, federal regulators said new portions of the 2024 rule would not be enforced while litigation and reconsideration proceed, though the underlying statutory parity obligation remains in force [10] — an unsettled area to verify before underwriting a deal.
• Medicaid / CMS reimbursement. Because Medicaid is the dominant payer, state Medicaid rate-setting drives provider economics [8]. Coverage or reimbursement changes cut both ways.
• Certified Community Behavioral Health Clinics (CCBHCs). A Medicaid demonstration paying clinics a cost-based prospective rate in exchange for a required service scope; made a permanent state-plan option under the Consolidated Appropriations Act of 2024, with new state cohorts phasing in through 2027 [14] — a funding tailwind for nonprofit/community providers.
• Opioid treatment programs. OTPs require SAMHSA certification under 42 CFR (Code of Federal Regulations) Part 8, DEA (Drug Enforcement Administration) registration (methadone is Schedule II), and state licensure. A 2024 SAMHSA rule modernized OTP standards and made pandemic-era take-home-dose flexibilities permanent [12].
• Telemedicine prescribing of controlled substances. DEA and HHS (the Department of Health and Human Services) finalized a rule (Jan. 2025) permitting up to a six-month supply of buprenorphine via telehealth before an in-person visit; broader COVID-era tele-prescribing flexibilities were extended again through Dec. 31, 2026 [13]. This annual "telehealth cliff" is a recurring risk.
• Privacy: HIPAA and 42 CFR Part 2. The Health Insurance Portability and Accountability Act (HIPAA) governs health data generally; the stricter Part 2 rules protect substance-use records. A 2024 final rule aligned Part 2 closer to HIPAA while preserving special protections, with a compliance date of Feb. 16, 2026 [11].
• Corporate practice of medicine. Many states bar non-physician ownership of clinical practices, forcing private-equity ownership into management-services-organization (MSO) / "friendly professional-corporation (PC)" structures rather than direct clinical control.
• Billing/documentation is a live enforcement risk. In 2025 the Department of Justice (DOJ) announced that a California behavioral-health provider agreed to pay $2.75 million to resolve allegations of improperly documented psychotherapy claims (the settlement was not a finding of liability) [31].

---

8. Competitive dynamics & consolidation

The defining feature is extreme fragmentation — CR4 of 3.8% and an HHI of 9.2 [2], among the lowest in health care — yet competition is local and payer-specific. Winners typically combine clinician recruiting/retention, payer-network access, referral relationships (primary care, hospitals, schools, employers), convenient in-person and virtual access, centralized scheduling/billing/compliance, and a credible outcomes record.

• Roll-ups. Private equity and public operators buy up solo practices and OTPs to build regional scale (LifeStance in outpatient psychiatry; BayMark, Acadia, New Season and Pinnacle in addiction treatment) [20]. Peer-reviewed research found private-equity-backed deals accounted for about 60% of behavioral-health acquisition activity studied over 2010–2021, most of it outpatient facilities [23]. The playbook — acquire, centralize non-clinical functions, expand payer access, add clinicians, raise utilization — is offset by clear failure modes: clinician attrition, weak integration, excess leverage, and compliance or reputational damage.
• Payer–provider convergence. Insurers are building or buying provider networks — Optum (UnitedHealth) and Evernorth (Cigna) — and UHS is acquiring Talkspace [17] for virtual outpatient reach. Vertical integration is reshaping who owns the patient.
• Digital marketplaces (Headway, Grow, Rula, Talkiatry) are a new distribution layer, aggregating independent clinicians into insurance networks and competing with brick-and-mortar groups for both patients and clinicians [21].
• Rising scrutiny. In 2024 the FTC, DOJ and HHS launched a cross-government inquiry into corporate/private-equity control in health care [29]; Senators Markey, Braun and Hassan opened parallel investigations into PE-owned OTP chains (Acadia, BayMark, New Season) over profits, staffing and access [22]. Market advisers describe 2026 behavioral-health M&A as still active but more selective amid regulatory scrutiny, possible Medicaid pressure, and a shift toward integrated, value-based care [30]; reporting suggests some private equity is beginning to retreat from addiction treatment, potentially reshaping who consolidates next.

Our read: consolidation continues, but the center of gravity is shifting from pure financial roll-ups toward payer-integrated and digitally distributed models.

---

9. Risks

• Reimbursement risk. Payers can cut rates, narrow networks, add prior authorization, or delay claims.
• Medicaid risk. Because revenue leans on government payers, state rate cuts, managed-care contract changes, budget pressure, or federal enrollment changes hit the top line directly.
• Labor risk. A structural clinician shortage means wage inflation, turnover and a hard ceiling on visit capacity [7]; productivity gains are slow in a one-clinician-one-patient service.
• Regulatory/political risk. Congressional and cross-agency scrutiny of PE-owned OTPs [22][29], uncertain parity enforcement [10], and annually renewed telehealth-prescribing flexibilities [13] all create policy risk.
• Clinical & reputational risk. Poor care, safety incidents, methadone-access controversies, or aggressive utilization can trigger lawsuits, sanctions or lost referrals in a sensitive care area.
• Billing risk. Inaccurate coding, unsupported services, weak documentation and improper referral arrangements create repayment and False Claims Act exposure [31].
• Privacy/cyber risk. Mental-health and substance-use records are especially sensitive; breaches carry regulatory, litigation and reputational cost.
• Consolidation & capital-structure risk. Integrating fragmented acquisitions is hard, and private platforms often use heavy debt — refinancing is difficult if reimbursement or margins weaken. Short-seller Hindenburg publicly questioned LifeStance's roll-up economics, and its 2023 clinic closures show the model can over-expand [15].
• Measurement risk. Federal business statistics omit meaningful parts of the market [4], complicating market-size and share estimates.
• Demand is defensive; revenue is not. Need is recession-resistant, but because it is funded so heavily by public budgets, revenue is policy-cyclical rather than economy-cyclical.

---

10. How to invest, and the outlook

Public routes. For a focused bet on insurance-billed outpatient mental health, LifeStance (LFST) is the pure-play; Acadia (ACHC) and UHS give diversified behavioral exposure weighted to inpatient/residential, with UHS adding virtual outpatient via the pending Talkspace (TALK) deal [17][18]. There is no dedicated behavioral-health ETF, so broad exposure comes only as a slice of healthcare-services or facilities funds. As a group these are growth/turnaround names, not income plays — reserve valuation multiples and dividend questions for the specific ticker, and treat TALK as a merger situation until the deal closes or fails.

Private routes. This is where most of the industry lives. Options range from platform buyouts and add-on practice acquisitions, to minority/growth equity, to direct lending, healthcare real estate, or enabling software — plus venture exposure in the digital marketplaces (Headway, Grow, Rula, Talkiatry) [21]. A diligence checklist should prioritize payer contracts, clinician ownership/employment arrangements (corporate-practice compliance), licensing, claims and denial history, accounts-receivable aging, referral concentration, outcomes data, patient-safety controls, and acquisition-adjusted leverage. The fragmentation that makes the field ripe for consolidation is exactly the private-market opportunity — now weighed against rising scrutiny of for-profit addiction care [22][29].

Near-term drivers to watch (forward-looking):

• Renewal or expiration of DEA telehealth-prescribing flexibilities beyond 2026 [13].
• Medicaid funding and enrollment policy — the single biggest swing factor for revenue [8].
• The direction of MHPAEA parity enforcement after the 2025 suspension [10].
• CCBHC expansion as a funding tailwind for community providers [14].
• Clinician supply and wage trends [7].
• Whether private equity's apparent retreat from addiction treatment opens acquisition openings for strategic and payer-owned buyers [22].

Our outlook: demand fundamentals are unusually durable — need is high, clinician supply is constrained, and outpatient care is cheaper and more accessible than inpatient — and the shift toward parity and virtual access is structurally favorable. But the industry is neither recession-proof nor automatically high-margin. The investable question is less "will demand grow" (it will) than "who captures the economics" — a contest among clinic roll-ups, payer-owned provider arms, and asset-light digital marketplaces, all operating on thin, labor-constrained margins under a policy-sensitive, Medicaid-heavy revenue base. The best businesses will turn scarce clinician capacity into reliable in-network access while keeping quality high and billing clean. Watch same-center visits, clinician retention, net reimbursement, denial rates, cash flow and leverage more closely than headline revenue growth.

---

Sources

1. U.S. Census Bureau, County Business Patterns (CBP): 2023 — NAICS 621420 establishments, employment, annual and Q1 payroll. https://www.census.gov/data/datasets/2023/econ/cbp/2023-cbp.html
2. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms — NAICS 621420 receipts, firm count, CR4/CR8/CR20/CR50, HHI. https://api.census.gov/data/2022/ecnsize/groups/EC2200SIZECONCEN.html
3. U.S. Census Bureau, 2022 NAICS definition — 621420, Outpatient Mental Health and Substance Abuse Centers (scope and cross-references to 621112, 621330, 622210, 623220). https://www.census.gov/naics/?details=621420&input=621420&year=2022
4. U.S. Census Bureau, CBP Methodology and Understanding NAICS / Economic Census coverage (exclusion of self-employed, government, and nonemployer businesses). https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html; https://www.census.gov/programs-surveys/economic-census/year/2022/guidance/understanding-naics.html
5. U.S. Small Business Administration, Table of Size Standards, 2023 — NAICS 621420, $19 million receipts. https://www.sba.gov/document/support-table-size-standards
6. Substance Abuse and Mental Health Services Administration (SAMHSA), 2024 National Survey on Drug Use and Health (NSDUH), 2025 — mental-illness prevalence and treatment gap. https://www.samhsa.gov/newsroom/press-announcements/20250728/samhsa-releases-annual-national-survey-on-drug-use-and-health
7. Health Resources and Services Administration (HRSA), Health Professional Shortage Areas (HPSA) Statistics, as of July 1, 2026. https://data.hrsa.gov/Default/GenerateHPSAQuarterlyReport/
8. Centers for Medicare & Medicaid Services (CMS), Medicaid Behavioral Health Services. https://www.medicaid.gov/medicaid/benefits/behavioral-health-services
9. CMS, The Mental Health Parity and Addiction Equity Act (MHPAEA) overview. https://www.cms.gov/marketplace/private-health-insurance/mental-health-parity-addiction-equity
10. U.S. Departments of Labor, Health and Human Services, and Treasury, Statement Regarding Enforcement of the 2024 MHPAEA Final Rule, 2025. https://www.cms.gov/files/document/statement-regarding-enforcement-final-rule-requirements-related-mhpaea.pdf
11. U.S. Dept. of Health and Human Services, Fact Sheet: 42 CFR Part 2 Final Rule (compliance date Feb. 16, 2026). https://www.hhs.gov/hipaa/for-professionals/regulatory-initiatives/fact-sheet-42-cfr-part-2-final-rule/index.html
12. SAMHSA, 42 CFR Part 8 Final Rule — Opioid Treatment Programs (2024 modernization; take-home flexibilities). https://www.samhsa.gov/substance-use/treatment/opioid-treatment-program/42-cfr-part-8
13. DEA / SAMHSA, Final telemedicine rule for buprenorphine (Jan. 2025) and fourth temporary extension of controlled-substance telemedicine flexibilities through Dec. 31, 2026. https://www.samhsa.gov/about/news-announcements/statements/2025/dea-and-hhs-issue-final-telemedicine-rule-for-buprenorphine-access; https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled
14. Medicaid.gov / SAMHSA, Certified Community Behavioral Health Clinic (CCBHC) Demonstration — permanent state-plan option (CAA 2024); state cohorts 2024–2027. https://www.medicaid.gov/medicaid/financial-management/certified-community-behavioral-health-clinic-ccbhc-demonstration; https://www.samhsa.gov/communities/certified-community-behavioral-health-clinics/section-223
15. LifeStance Health, FY2024 and FY2025 results and 2025 Form 10-K (FY2025 revenue $1,424.3 M; 8,040 clinicians; ~9.0 M visits; 550+ centers; center margin ~32%; 82 clinics closed in 2023). https://www.sec.gov/Archives/edgar/data/1845257/000119312526071462/lfst-20251231.htm; https://investor.lifestance.com/news-releases/news-release-details/lifestance-reports-fourth-quarter-and-full-year-2025-results
16. Acadia Healthcare, 2025 Form 10-K and FY2024/Q1 2026 results (277 facilities, 12,500+ beds, 40 states + Puerto Rico; payer mix ~57% Medicaid; 165 Comprehensive Treatment Centers; CTC revenue $140.4 M in Q1 2026). https://www.sec.gov/Archives/edgar/data/1520697/000119312526078266/achc-20251231.htm; https://www.sec.gov/Archives/edgar/data/1520697/000143774926005431/ex_924499.htm
17. Universal Health Services, 2025 Form 10-K (346 behavioral-health facilities incl. 119 outpatient) and UHS to Acquire Talkspace announcement ($5.25/share, ~$835 M). https://www.sec.gov/Archives/edgar/data/352915/000119312526071676/uhs-20251231.htm; https://www.prnewswire.com/news-releases/universal-health-services-inc-to-acquire-talkspace-inc-302708096.html
18. Talkspace, Stockholders Vote to Approve Acquisition by UHS (May 2026; close expected Q3 2026) and FY2025 Form 10-K. https://talkspace.gcs-web.com/news-releases/news-release-details/talkspace-stockholders-vote-approve-acquisition-uhs; https://www.sec.gov/Archives/edgar/data/1803901/000119312526105146/talk-20251231.htm
19. Fierce Healthcare / Wikipedia, LifeStance Health — TPG buyout (2020), 2021 IPO, sponsor ownership. https://www.fiercehealthcare.com/tech/lifestance-health-valued-at-more-than-7b-as-stock-jumps-following-ipo; https://en.wikipedia.org/wiki/Lifestance_Health
20. BayMark Health Services, About Us — largest U.S. opioid-treatment provider, 400+ facilities across 35 states. https://baymark.com/about-us/
21. Sacra / Tracxn / Behavioral Health Business, Headway (~$2.3 bn valuation), Grow Therapy (unicorn), Rula (~$470 M revenue), Talkiatry funding and scale, 2024–2026. https://sacra.com/c/headway/; https://sacra.com/research/rula-at-471m-year-growing-100-yoy/; https://bhbusiness.com/2025/12/17/uwill-rula-health-talkiatry-lifemd-rank-on-deloittes-fast-500/
22. Behavioral Health Business / Health Affairs / U.S. Senate, Private-equity ownership of opioid treatment programs and 2024–25 congressional inquiries. https://bhbusiness.com/2024/03/19/nearly-one-third-of-otps-are-owned-by-private-equity-firms/; https://www.markey.senate.gov/news/press-releases/senators-markey-braun-push-opioid-treatment-programs-for-answers-on-private-equity-investments
23. Thornburg et al., Acquisitions of Behavioral Health Treatment Facilities from 2010 to 2021, Health Affairs Scholar, 2024. https://doi.org/10.1093/haschl/qxae080
24. Behavioral Health Business, How Mindpath is Scaling to a National Behavioral Health Brand (Centerbridge Partners; Leonard Green & Partners), 2021. https://bhbusiness.com/2021/12/12/how-mindpath-is-scaling-to-a-national-behavioral-health-brand/
25. Onex, Onex Partners Completes Majority Investment in Newport Healthcare, 2021. https://www.onex.com/article/2021NewsRelease-OnexCompletesNewportHealthcare-July19
26. Discovery Behavioral Health, About / 2026 restructuring and ownership change. https://discoverybehavioralhealth.com/
27. BrightView Health, About BrightView Health. https://www.brightviewhealth.com/about-us/
28. Connections Health Solutions, About Us. https://connectionshs.com/about
29. Federal Trade Commission, DOJ, and HHS, Cross-Government Inquiry on Corporate Control in Health Care, 2024. https://www.ftc.gov/news-events/news/press-releases/2024/03/federal-trade-commission-department-justice-department-health-human-services-launch-cross-government
30. Capstone Partners, Behavioral Healthcare Services M&A Update, 2026. https://www.capstonepartners.com/insights/report-behavioral-health-services-ma-update/
31. U.S. Department of Justice, California Behavioral Medicine Provider Agrees to Pay $2.75 Million to Resolve Alleged False Claims, 2025. https://www.justice.gov/usao-ndca/pr/california-behavioral-medicine-provider-agrees-pay-275-million-resolve-alleged-false
32. IBISWorld, Mental Health & Substance Abuse Centers in the US — Market Size, 2025. https://www.ibisworld.com/united-states/market-size/mental-health-substance-abuse-centers/1597/